Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Kosiborod, Mikhail; Kosiborod, Mikhail; S.P. Lam, Carolyn; Kohsaka, Shun; Jung Kim, Dae; Karasik, Avraham; E. Shaw, Jonathan; Tangri, Navdeep; Goh, Su‐Yen; Thuresson, Marcus; Chen, Hungta; Surmont, Filip; Hammar, Niklas; Fenici, Peter; Kosiborod, Mikhail; Kosiborod, Mikhail; A. Cavender, Matthew; Z. Fu, Alex; Wilding, John; Khunti, Kamlesh; Norhammar, Anna; I. Birkeland, Kåre; E. Jørgensen, Marit; W. Holl, Reinhard; S.P. Lam, Carolyn; Løvdal Gulseth, Hanne; Carstensen, Bendix; Bollow, Esther; Franch‐Nadal, Josep; A. Garcı́a Rodrı́guez, Luis; Karasik, Avraham; Tangri, Navdeep; Kohsaka, Shun; Jung Kim, Dae; E. Shaw, Jonathan; V. Arnold, Suzanne; Goh, Su‐Yen; Hammar, Niklas; Fenici, Peter; Bodegård, Johan; Chen, Hungta; Surmont, Filip; Nahrebne, Kyle; T. Blak, Betina; Wittbrodt, Eric; Saathoff, Matthias; Noguchi, Yusuke; Tan, Donna; R. I. Williams, Maro; Won Lee, Hye; Greenbloom, Maya; Kaidanovich‐Beilin, Oksana; Keong Yeo, Khung; Mong Bee, Yong; Khoo, Joan; Koong, Agnes; How Lau, Yee; Gao, Fei; Boon Tan, Wee; Abdul Kadir, Hanis; Hwa Ha, Kyoung; Lee, Jinhee; Chodick, Gabriel; Melzer Cohen, Cheli; Whitlock, Reid; Cea Soriano, Lucía; Fernández Cantero, Oscar; Riehle, Ellen; Ilomäki, Jenni; J. Magliano, Dianna

doi:10.1016/j.jacc.2018.03.009

Public

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Published in Journal of the American College of Cardiology • Mar 14, 2018

Authors:

Mikhail Kosiborod

Carolyn S.P. Lam

Abstract

BACKGROUND: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, ...

Subject

Empagliflozin

Dapagliflozin

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!